Adverse events · patients with non‐specific acute and subacute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain: intermediate‐term · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Disability 1 week (immediate term) (RMDQ 0 to 24) · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Disability (intermediate‐term) RMDQ. Scale from: 0 to 24. · patients with non‐specific acute and subacute low back pain
1 finding from 1 review
Adverse events · patients with non‐specific acute and subacute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time (days) to achieve exclusive oral feeding · preterm infants
1 finding from 1 review
Time (days) spent in NICU ‐ not reported · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · preterm infants
1 finding from 1 review
Duration (days) of parenteral nutrition · preterm infants
1 finding from 1 review
ADHD symptoms · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes ADHD symptoms: all parallel‐group trials and first‐period cross‐over… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Proportion of participants with one or more serious adverse events · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious (penicillin versus doxycycline) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes proportion of participants with one or more adverse events… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
General behaviour: all parallel‐group trials and first‐period cross‐over trials General behaviour rating scales (Teacher‐rated) · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes general behaviour: all parallel‐group trials and first‐period… compared with placebo or no intervention (very low certainty).
1 finding from 1 review
QoL · Children and adolescents with ADHD
It is very uncertain whether methylphenidate changes quality of life (parent‐rated) compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Perioperative mortality · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes perioperative mortality Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Serious adverse events Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative transfusion Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative transfusion Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Reoperation Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes reoperation Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative bile leak Median · adults undergoing liver resection for cancer or benign disease
It is very uncertain whether fibrin‐based haemostatic agents changes postoperative bile leak Median compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Mortality ‐ total number · prevention and treatment of hepatic encephalopathy in people with cirrhosis
Summary of findings table ‐ Rifaximin showed no clear difference in mortality ‐ total number compared with placebo/no intervention (moderate certainty).
1 finding from 1 review